(Q39227095)

10 September 2017

1 reference

title

Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis (English)

1 reference

10 September 2017

0 references

Choy EH

1

1 reference

10 September 2017

1 February 1998

1 reference

10 September 2017

1 reference

10 September 2017

12

1 reference

10 September 2017

2

1 reference

10 September 2017

139-148

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199812020-00006

10 September 2017

0 references

cites work

Cytokines in autoimmunity

1 reference

12 December 2020

Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody

1 reference

12 December 2020

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

12 December 2020

Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells

1 reference

12 December 2020

Adhesion molecules in rheumatoid arthritis: role in the pathogenesis and prospects for therapy

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis

1 reference

12 December 2020

Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone

1 reference

12 December 2020

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

12 December 2020

Synovial tissue response to treatment with Campath-1H

1 reference

12 December 2020

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis

1 reference

12 December 2020

Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis

1 reference

12 December 2020

Long-term outcome of treating rheumatoid arthritis: results after 20 years

1 reference

12 December 2020

How important are T cells in chronic rheumatoid synovitis?

1 reference

12 December 2020

Both macrophages and endothelial cells of the human hepatic sinusoid express the CD4 molecule, a receptor for the human immunodeficiency virus

1 reference

12 December 2020

Phage libraries--a new route to clinically useful antibodies

1 reference

12 December 2020

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

12 December 2020

TNF alpha--a pivotal role in rheumatoid arthritis?

1 reference

12 December 2020

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens

1 reference

12 December 2020

Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody

1 reference

12 December 2020

CD7- T cells in rheumatoid arthritis

1 reference

12 December 2020

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

12 December 2020

Immunotherapeutic approach to rheumatoid arthritis with anti-idiotypic antibodies to HLA-DR4.

1 reference

12 December 2020

Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody

1 reference

12 December 2020

Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis

1 reference

12 December 2020

Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody

1 reference

12 December 2020

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

1 reference

12 December 2020

Macrophage activation by T cells

1 reference

12 December 2020

Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69.

1 reference

12 December 2020

The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis

1 reference

12 December 2020

Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration

1 reference

12 December 2020

Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair

1 reference

12 December 2020

Adverse reactions to Campath-1H monoclonal antibody

1 reference

12 December 2020

Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone

1 reference

12 December 2020

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

12 December 2020

1 reference

12 December 2020

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

1 reference

12 December 2020

Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis

1 reference

12 December 2020

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

1 reference

12 December 2020

Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience

1 reference

12 December 2020

Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis

1 reference

12 December 2020

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate

1 reference

12 December 2020

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

1 reference

12 December 2020

10.2165/00002512-199812020-00006

Identifiers

DOI

1 reference

PubMed ID

9509292

Dimensions Publication ID

10 September 2017

1019961836

0 references

Fatcat ID

release_5anryyzo6vhbthkadylajoj6ui

0 references

PubMed ID

9509292

1 reference

PubMed ID

9509292